Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors
September 13 2017 - 4:15PM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) today announced that its
Board of Directors has elected Karen Vousden, Ph.D., to the Board,
effective January 1, 2018. Dr. Vousden will serve as a member of
the Science and Technology Committee of the Board of Directors.
Dr. Vousden, 60, is currently group leader at the Francis Crick
Institute in London and the Chief Scientist at Cancer Research UK,
where she is responsible for focusing on the role of basic science
in the treatment of cancer. She brings to the Board more than 30
years of experience leading groundbreaking cancer research, having
served in her current role since 2016 and in the role of Director
of the Beatson Institute for Cancer Research from 2002 to 2016. She
also held leadership roles at the National Cancer Institute from
1995 to 2002. She has served on the Board of the American
Association for Cancer Research.
"Karen is a world class cancer researcher and a highly
accomplished leader in her field,” said Giovanni Caforio,
M.D., chairman and chief executive officer, Bristol-Myers Squibb.
“Her understanding of cancer biology and immunology research will
bring valuable insights to advancing our strategy and strong
pipeline in oncology along with our broader pipeline of
transformational medicines.”
“Karen brings to the Board deep scientific expertise developed
through a successful career in research, including her current
leadership role at one of the world’s most influential cancer
research organizations,” said Vicki L. Sato, Ph.D., lead
independent director, Bristol-Myers Squibb. “Karen’s focus on
cancer biology and translational medicine lend an important
perspective to the Board and we look forward to her
contributions.”
“Bristol-Myers Squibb has been at the forefront of researching
and developing new therapies that harness the immune system to
fight cancer,” said Dr. Vousden. “It’s a tremendous honor to be
appointed to the Board, and I look forward to working with
Giovanni, his leadership team and the rest of the Board during this
unprecedented moment in cancer research.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, and YouTube.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913006036/en/
Bristol-Myers SquibbMedia:Laura Hortas,
609-252-4587laura.hortas@bms.comorKen Dominski,
609-252-5251ken.dominski@bms.comorInvestors:Tim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024